论文部分内容阅读
目的:比较银杏叶提取物(EGb)、卡托普利和缬沙坦对链脲佐菌素(STZ)诱导的糖尿病肾病(DN)模型大鼠的保护作用。方法:以STZ诱导建立大鼠糖尿病模型。随机分为正常对照组、病理模型组及EGb、卡托普利、缬沙坦治疗组。给药12周后,比较各组大鼠的生理状况、肾组织及血液中AGEs含量、抗氧化指标活性、生化指标等。结果:EGb、卡托普利和缬沙坦对糖尿病肾病模型大鼠的生理状况有明显改善,对AGEs含量、肾脏指数、血糖(Glu)、血肌酐(Cr)、尿素氮(BUN)、24 h尿蛋白及抗氧化指标CAT、T-AOC、SOD、GSH-Px等活性有不同程度的影响,其中EGb在改善肾脏功能和提高抗氧化指标活性方面作用明显,与卡托普利、缬沙坦相比有显著性差异。结论:EGb、卡托普利和缬沙坦均能预防糖尿病模型大鼠DN的形成,EGb对糖尿病肾病的保护作用强于卡托普利和缬沙坦。
Objective: To compare the protective effects of Ginkgo biloba extract (EGb), captopril and valsartan on streptozotocin (STZ) -induced diabetic nephropathy (DN) in rats. Methods: The rat model of diabetes was induced by STZ induction. Randomly divided into normal control group, pathological model group and EGb, captopril, valsartan treatment group. After 12 weeks of administration, the physiological status of rats in each group, the content of AGEs in kidney tissue and blood, the activity of antioxidant index and the biochemical indexes were compared. RESULTS: EGb, captopril and valsartan significantly improved the physiological status of rats with diabetic nephropathy. The levels of AGEs, renal index, Glu, serum creatinine, BUN and 24 h Urinary protein and antioxidant index CAT, T-AOC, SOD, GSH-Px and other activities have varying degrees of effect, including EGb in improving renal function and improve the activity of antioxidant indicators significantly, with captopril, valsartan Compared to significant differences. CONCLUSION: Both EGb, captopril and valsartan can prevent the formation of DN in diabetic rats. EGb has a stronger protective effect on diabetic nephropathy than captopril and valsartan.